CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 17 enrolled
Drug / intervention
PSA RNA-pulsed dendritic cell vaccinebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00004211
NCT00004211Phase 2Completed
CompareCT.gov

A Safety and Feasibility Study of Active Immunotherapy in Patients With Metastatic Prostate Carcinoma Using Autologous Dendritic Cells Pulsed With RNA Encoding Prostate Specific Antigen, PSA

Duke University·interventional·Posted May 20, 2004·Updated Mar 21, 2013

In Brief

A Phase 2 clinical trial evaluating PSA RNA-pulsed dendritic cell vaccine for Prostate Cancer. Completed, enrolled 17 participants across 1 site.

Detailed Summary

RATIONALE: Vaccines may make the body build an immune response to kill tumor cells. PURPOSE: Phase I/II trial to study the effectiveness of vaccine therapy in treating patients who have metastatic prostate cancer.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsProstate Cancer
CountriesUnited States
CollaboratorsNational Cancer Institute (NCI)

Timeline

Phase 2CompletedFinished
19992000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedMay 20, 2004
Enrollment StartJul 1, 1999
Study CompletionJan 1, 2002
TodayJul 2, 2026
Posted 22.1 years ago

Interventions

PSA RNA-pulsed dendritic cell vaccinebiological